JPMorgan Lifts PT on Crinetics Pharmaceuticals (CRNX) to $52 From $53, Keeps an Overweight Rating

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best strong buy stocks to invest in according to Wall Street. On September 24, JPMorgan analyst Jessica Fye lowered the firm’s price target on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) to $52 from $53 while keeping an Overweight rating on the shares.

Is Crinetics Pharmaceuticals Inc. (CRNX) the Worst Performing Mid Cap Stock to Buy According to Analysts?

The firm told investors that it updated Crinetics Pharmaceuticals, Inc.’s (NASDAQ:CRNX) model to reflect slightly higher spending assumptions.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage pharmaceutical company that develops and commercializes novel therapeutics for rare endocrine diseases and endocrine-related tumors.

The company’s product candidate, CRN00808, is an oral treatment for acromegaly. It is also developing other oral treatments for neuroendocrine tumors, hyperinsulinism, and Cushing’s disease.

While we acknowledge the potential of CRNX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CRNX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.